Doha
FOLLOWING the award of a five-year programme funding by Qatar Foundation’s Qatar National Research Fund and co-funded by Hamad Medical Corporation (HMC) through the Academic Health System (AHS), the region’s largest diabetes research project, the Qatar Diabetes Prevention Programme (QDPP) is all set to begin.
“Diabetes is one of the most pressing health conditions in Qatar. It is estimated that at least 17 percent of the adult Qatari population has diabetes and this number is expected to"...

The Advisors to the International EMF Scientist Appeal, representing 248 scientists from 42 nations, have resubmitted The Appeal to the United Nations Environment Programme (UNEP) Executive Director, Inger Andersen, requesting the UNEP reassess the potential biological impacts of next generation 4G and 5G telecommunication technologies to plants, animals and humans.

There is particular urgency at this time as new antennas will be densely located"...

Doha: Hamad Medical Corporation’s Al Wakrah Hospital, the country’s second busiest hospital is set to increase its bed capacity by 10 percent in 2020 to meet the growing demand.

The hospital will also have a dedicated facility for children in need of long-term care next year as well as a cath lab for patients with cardiac problems as part of the ongoing expansion plan, said Dr Sabah Alkadhi, Medical Director of Al Wakrah Hospital.

Doha: Hamad Medical Corporation’s (HMC) newest hospital, Hazm Mebaireek General Hospital (HMGH) has completed the first phase of its surgical services implementation programme.

Two operating theatres for elective general surgery and urology procedures are now open, and upwards of 15 surgeries are expected to be performed each week as part of the initial phase of the implementation of the new service.

Dr"...

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat.

“Oral"...

The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health"...

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.

Both companies will initially focus"...

With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF) are speaking out loudly—declaring"...

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029.

Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings"...